Submit Content
Get the latest delivered to your inbox
Privacy Policy

International Childhood Cancer Day Announcement: Global Hope, Teva and Direct Relief Partner to Bring Medicines to Help Improve the Lives of Children With Cancer in Africa

Published 02-14-20

Submitted by Teva Pharmaceuticals

Global HOPE (Hematology-Oncology Pediatric Excellence), a program of Texas Children’s Hospital, Teva Pharmaceutical Industries Ltd. and Direct Relief announced today a donation partnership that will provide access to medications in sub-Saharan Africa—where an overwhelming majority of pediatric cancer and hematology patients do not survive.

Under this partnership, Global HOPE will determine the specific volumes and quantities of medications identified for current patient needs at its clinical sites. Teva will provide essential medications for treating cancer and blood disorders in children to Direct Relief, who will in turn ensure the efficient shipping and delivery of the donated medicines in coordination with Global HOPE facilities. 

“The success we’ve had in radically changing the course of pediatric cancer and hematology in sub-Saharan Africa is due in large part to our partners and donors who have made our work possible,” said Dr. David Poplack, Director of Global HOPE. “By partnering with a global leader in generic and specialty medicines like Teva along with Direct Relief’s experience in cold chain logistics, we can have an immediate and sustained impact in low- and middle-income countries where increased access to pediatric oncology treatments is desperately needed.”

Teva will initially support the Global HOPE program in Malawi, with the potential to extend access of donated medicines to other Global HOPE sites across sub-Saharan Africa. Teva’s donation of medicines through this partnership will support the treatment plans for almost 95% of all chemotherapy patients. Over the next five years, Global HOPE anticipates diagnosing and treating close to 4,000 new pediatric cancer patients in Malawi.

“This initiative with Global HOPE and Direct Relief can bring medicines to thousands of children with cancer and blood disorders in African countries,” said Amalia Adler-Waxman, VP Social Impact and Responsibility at Teva. “Supporting this critical supply chain along with our partners allows us to facilitate access to pediatric oncology treatments while laying the groundwork for Global HOPE and others to also potentially treat pediatric illnesses beyond cancer and hematologic disorders.”

As an organization with decades of global supply chain and logistics expertise, Direct Relief will play a leading role in the distribution of donated prescriptions product from Teva. Direct Relief’s shipments of donated medicines from Teva will be shipped to one of the designated local Global HOPE-affiliated NGOs in Malawi, Botswana and Uganda.

“Direct Relief is deeply appreciative to Teva and Global HOPE for their leadership and initiative in providing critical treatments to children in Africa and globally,” said Thomas Tighe, President and CEO of Direct Relief. “Thanks to this collaboration, children who would otherwise be unable to access cancer therapies will be able to receive the treatments they need.”

The partnership was announced for International Childhood Cancer Day. International Childhood Cancer Day is a global collaborative campaign to raise awareness and promote an increased appreciation and deeper understanding of the challenges faced by children and adolescents with cancer, the survivors and their families. 

About Direct Relief
A humanitarian organization committed to improving the health and lives of people affected by poverty or emergencies, Direct Relief delivers lifesaving medical resources throughout the world to communities in need—without regard to politics, religion, or ability to pay. For more information, please visit https://www.DirectRelief.org.

About Global HOPE
Global HOPE (Hematology-Oncology Pediatric Excellence) is focused on building long term capacity to treat and dramatically improve the prognosis for children with cancer and blood disorders in Sub-Saharan Africa. Launched in 2017, as a program of Texas Children’s Hospital and Baylor College of Medicine and, supported by a $50 million foundational investment from Bristol-Myers Squibb Foundation, Global HOPE is strengthening local healthcare infrastructure and building capacity to effectively provide the multi-disciplinary care that is needed to optimally care for children with cancer and blood disorders. Work is already underway in Uganda, Malawi, and Botswana where, since its inception, Global HOPE  has treated over 8,000 hematology and oncology patients with remarkable success and trained over 1,800 healthcare professionals. Other African nations, including Eswatini, Lesotho, Rwanda and Tanzania, are in the plans for expansion. 

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences are discussed in our Quarterly Reports on Form 10-Q for the first, second and third quarter of 2019 and in our Annual Report on Form 10-K for the year ended December 31, 2018, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

For Media Inquiries, please contact:

  • Jenna Stoklosa at Red Havas; +1 (203) 300 – 4108

  • Marc Boston at Teva Pharmaceuticals; +1 (973) 307 – 4885          

Teva Pharmaceuticals Logo

Teva Pharmaceuticals

Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.

More from Teva Pharmaceuticals

Join today and get the latest delivered to your inbox